CureVac NV

As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V. is a biopharmaceutical company focused on developing transformative medicines based on messenger ribonucleic acid (mRNA). Its portfolio includes clinical and preclinical candidates for prophylactic vaccines, oncology, and molecular therapy. The company also offers The RNA Printer, an automated process for manufacturing mRNA vaccines and therapeutics, and develops vaccine candidates such as CV0601 and CV0701 against SARS-CoV-2, and CVGBM for cancer. Incorporated in 2000, CureVac N.V. is headquartered in Tübingen, Germany.